Jason John Luke
University of Pittsburgh
H-index: 54
North America-United States
Top articles of Jason John Luke
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Nivolumab+ Tacrolimus+ Prednisone±Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers | Journal of Clinical Oncology | Kara M Schenk Julie Stein Deutsch Sunandana Chandra Diwakar Davar Zeynep Eroglu | 2024/1/22 |
Rapidly Evolving Pre-and Post-surgical Systemic Treatment of Melanoma | Ryan C Augustin Jason J Luke | 2024/2/26 | |
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade | Clinical Cancer Research | Richard C Wu Jason J Luke | 2024/1/5 |
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy | Clinical Cancer Research | Paolo DA Vignali Jason J Luke | 2024/3/5 |
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study | The Lancet | Jeffrey S Weber Matteo S Carlino Adnan Khattak Tarek Meniawy George Ansstas | 2024/2/17 |
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma | medRxiv | Alexandra Tompkins Zane N Gray Rebekah E Dadey Serafettin Zenkin Nasim Batavani | 2024 |
Facts and hopes in using omics to advance combined immunotherapy strategies | Ryan C Augustin Wesley L Cai Jason J Luke Riyue Bao | 2024/2/9 | |
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors | Cancer Chemotherapy and Pharmacology | Claire Miller Roberto Sommavilla Cindy L O’Bryant Minal Barve Afshin Dowlati | 2024/4/20 |
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease | Journal for Immunotherapy of Cancer | Jason J Luke Diwakar Davar Robert H Andtbacka Nina Bhardwaj Joshua D Brody | 2024 |
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma | Rachel A Fischer Isabel Ryan Kristine De La Torre Cody Barnett Viren S Sehgal | 2024/2/8 | |
Th2 Cells Are Associated with Tumor Recurrence Following Radiation | Cancers | Mohamed K Abdelhakiem Riyue Bao Phillip M Pifer David Molkentine Jessica Molkentine | 2024/4/20 |
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors | Journal for immunotherapy of cancer | Nikhil I Khushalani Patrick A Ott Robert L Ferris Tina Cascone Dirk Schadendorf | 2024 |
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors | ESMO open | B Perez R Aljumaily TU Marron MR Shafique H Burris | 2024/2/1 |
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study | Jason J Luke Paolo Antonio Ascierto Muhammad Adnan Khattak Luis de la Cruz Merino Michele Del Vecchio | 2023/6/10 | |
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma–Authors' reply | The Lancet Oncology | Georgina V Long Jason J Luke Mizuho Fukunaga-Kalabis Paolo A Ascierto | 2023/1/1 |
Interferon Biology and LAG-3 Shedding in PD-(L) 1 plus LAG-3 Immunotherapy | Clinical Cancer Research | Lilit Karapetyan Jason J Luke | 2023/3/1 |
CT251/14-Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors | J Luke Rachel E Sanborn | 2023 | |
Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof | 2023/5/2 | ||
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors. | Anwaar Saeed Babar Bashir Jason J Luke Reuven Chantre Shira Amsili | 2023/6/1 | |
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition | European Journal of Cancer | Robert Ferguson Vylyny Chat Leah Morales Danny Simpson Kelsey R Monson | 2023/8/1 |
Co-Authors
